Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: March 7, 2019
Reporting Period: Quarter and year ended December 31, 2018
Status: Emerging Growth Company
Key Financial Metrics
This Form 8-K serves as a notification of the announcement of financial results. The specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not contained within the text of this filing. The filing states that the full details are provided in the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided source text.
Material Changes
The filing does not provide specific data points to compare against prior periods. It only confirms that results for the quarter and year ended December 31, 2018, were announced on March 7, 2019.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) for the full announcement but does not include specific guidance, outlook, or management commentary in the body text.
Legal Disclaimer: The information in this report is furnished to comply with Item 2.02 and is not deemed "filed" under Section 18 of the Exchange Act, nor is it subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 7, 2019) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate, as this is a pre-revenue or early-stage biotech firm.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of the company's emerging growth company election and its impact on financial reporting standards.